Question Id: 1176

Item 17 of 29 5 v Mark <q Se r j @ Ã©l fcc] Pr

A study is designed to evaluate the efficacy of a new drug, KM28. The study will compare

KM28 plus standard care versus standard care alone with regard to decreasing the incidence

of recurrent breast cancer. The Food and Drug Administration (FDA) will approve the new

drug if KM28 plus standard care decreases the rate of breast cancer recurrence by at least

40% compared to standard therapy alone. The recurrence rate on standard therapy is found
to be 8%. In order for the FDA to approve KM28, what is the maximal incidence of recurrent
disease acceptable for women treated with KM28 plus standard therapy?

J D.4.8% (62%)

A. 2.8% (2%)
B. 3.2% (23%)
C. 3.6% (7%)

E. 5.2% (3%)

Grantee 62% 04 secs ay 2022
Correct answer ail

. Answered correctly Time Spent [3] Version Adve Windlans

Block Time Elapse

Tutor

Feedback

GAA)

e r
Previous Next Full Screen Tutorial Lab Values Notes Calculator Reverse Color __Text Zoom

id

63

Settings

End Block
